In addition to FDG, another radiopharmaceutic, 18F-fluoroestradiol (FES) may emerge in the future as a complementary imaging tool characterizing noninvasively additional tumor features, related to the expression of ER [31]. The gene discussed is ESR1; the disease is neoplasm.